Legg Mason Global Infrastructure ETF
Will Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Comparing Revenue Growth Trends for AMRN and IOVA
In its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which represents a YoY rise of more than 50%.
What Are Analysts Recommending for AMRN and IOVA in May?
The consensus recommendation for Amarin in May is a “strong buy,” while the consensus recommendation for Iovance Biotherapeutics is a “buy.”
Mirati Therapeutics Stock Has Delivered Solid Growth in 2018
On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.
Iovance Biotherapeutics: The News That Drove Up the Stock
On October 12, Iovance Biotherapeutics (IOVA) stock rose 19.66% to $11.93 after the announcement of the price for its public offering.